RE:RE:RE:RE:(TSXV:BTI.V; OTCQB:BIOAF): 4th Quarter/YE StatementsI know who the two contract disputes were with but I can't say who they were. KayakerBC is correct, they do not reference partners and both are old news.
When the trolls, by admission, don't read posts longer than a sentence ir two and they then try to isolate an issue out of context, they do not reflect at all on the increasing complexity of what we know and don't know about Bioasis.
Bioasis is getting increasingly difficult to assess. For instance, my questions and concerns about disclosures are not meant to infer that the answers are negative. They infer that the answers are unknown, but could be completely positive. The market hates uncertainty.
As I stated about the Chiesi deal, any delays could be related to Covid and the delayed FDA inspections of Protalix manufacuring facilities and processes, delaying FDA approval of PRX-102. It would make sense for Chiesi to hold off on an xB3 version of PRX-102 until PRX-102 is approved. If PRX-102 is ultimately not approved, which would be a major surprise, then an xB3 version of it or any other drug made by Protalix with ProCellEx could be very unlikely.
Finallytherock just posted a poorly informed opinion about Chiesi and misrepresented my question as a negative statement. I will address that type of trolling. He doesn't have enough knowledge to comment on complex subjects. Otherwise, I don't care what he says about me. Personal attacks are just part of the social media world. Cowards always are big mouths when they're anonymous.
jd